statements

Gujarat Themis Biosyn Ltd.

BSE: 506879

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

369.60-0.5 (-0.14%)

17 Jul, 12:00 AM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Gujarat Themis Biosyn Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	8.71	28.37	30.23	31.44	32.62	35.69	38.80	41.05	85.12	90.56	114.85	148.97	169.82	150.80	165.82
Cost of Operating Revenue	8.42	18.36	18.72	1.67	20.72	23.18	25.20	25.81	12.70	17.10	18.85	59.76	72.20	64.17	72.39
Gross Profit	0.29	10.01	11.51	29.77	11.91	12.51	13.60	15.24	72.42	73.46	96.01	89.21	97.62	86.63	93.44
Gross Margin	3.3	35.3	38.1	94.7	36.5	35.0	35.1	37.1	85.1	81.1	83.6	59.9	57.5	57.5	56.3
Total Operating Expenses	12.11	26.15	25.15	26.25	27.79	30.76	33.71	34.94	54.65	51.97	59.04	77.33	94.62	87.33	103.21
Operating Profit	-3.40	2.21	5.08	5.19	4.84	4.93	5.09	6.11	30.48	38.60	55.81	71.64	75.20	63.47	62.61
Operating Margin	-39.0	7.8	16.8	16.5	14.8	13.8	13.1	14.9	35.8	42.6	48.6	48.1	44.3	42.1	37.8
Financing Income/(Expense) - Net	-1.06	-0.78	-0.71	-0.39	-0.38	-0.41	-0.42	-0.13	-0.92	-0.98	-0.83	4.22	3.80	0.33	-2.95
Profit before Taxes	1.59	1.07	4.53	4.59	4.63	4.88	4.84	8.20	31.26	40.88	59.03	77.46	79.33	65.54	62.09
Income Taxes	-	-	-	-	-	0.51	0.97	1.79	7.58	10.70	15.41	19.50	20.17	16.77	15.41
Profit after Tax	1.59	1.07	4.53	4.59	4.63	4.38	3.87	6.41	23.67	30.18	43.62	57.97	59.16	48.77	46.68
PAT Margin	18.2	3.8	15.0	14.6	14.2	12.3	10.0	15.6	27.8	33.3	38.0	38.9	34.8	32.3	28.2
EPS - Basic - ex Extraordinary Items	0.18	0.10	0.42	0.42	0.42	0.40	0.35	0.59	2.17	2.77	4.00	5.32	5.43	4.48	4.28
EPS - Diluted - ex Extraordinary Items	0.18	0.10	0.42	0.42	0.42	0.40	0.35	0.59	2.17	2.77	4.00	5.32	5.43	4.48	4.28
EBIT	-3.40	2.21	5.08	5.19	4.84	4.93	5.09	6.11	30.48	38.60	55.81	71.64	75.20	63.47	62.61
EBITDA	-2.29	3.64	6.54	6.56	6.04	6.05	6.24	7.33	31.84	40.33	58.05	74.22	79.26	69.12	75.53
EBITDA Margin	-26.3	12.8	21.6	20.9	18.5	16.9	16.1	17.9	37.4	44.5	50.5	49.8	46.7	45.8	45.5

Balance Sheet

Abridged

Understanding Balance Sheet

Gujarat Themis Biosyn Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	4.83	3.90	3.34	3.48	3.13	8.25	7.84	8.35	28.70	63.32	78.39	60.85	47.56	51.97	88.78
Long-Term Investments	0.01	0.01	0.01	0.01	0.30	0.27	0.17	6.26	15.54	1.30	9.21	0.40	31.04	0.94	0.93
Property Plant & Equipment - Net	11.41	12.42	11.18	9.74	9.41	10.83	10.76	15.56	17.44	21.02	32.13	53.26	129.24	225.54	410.02
Total Non-Current Assets	12.66	14.16	12.69	11.24	11.55	13.18	12.65	24.41	35.38	24.94	44.11	105.48	173.55	249.34	414.64
Total Assets	17.49	18.06	16.04	14.71	14.68	21.43	20.49	32.76	64.08	88.26	122.50	166.33	221.11	301.31	503.43
Total Current Liabilities	26.85	20.61	15.03	9.81	9.32	11.90	7.92	12.81	17.34	15.82	17.16	15.28	16.16	20.56	79.15
Long Term Debt	4.24	7.01	6.02	5.28	1.05	0.72	-	-	3.18	1.00	0.42	-	1.22	29.64	128.72
Total Non-Current Liabilities	4.50	7.33	6.35	5.69	1.52	1.32	0.46	1.43	4.54	2.49	2.02	1.90	3.58	32.37	136.51
Total Liabilities	31.35	27.93	21.38	15.50	10.83	13.22	8.38	14.24	21.88	18.32	19.18	17.18	19.74	52.93	215.66
Total Shareholders' Equity	-13.86	-9.87	-5.34	-0.79	3.84	8.21	12.11	18.52	42.20	69.95	103.32	149.15	201.38	248.38	287.77
Total Equity	-13.86	-9.87	-5.34	-0.79	3.84	8.21	12.11	18.52	42.20	69.95	103.32	149.15	201.38	248.38	287.77
Total Liabilities & Equity	17.49	18.06	16.04	14.71	14.68	21.43	20.49	32.76	64.08	88.26	122.50	166.33	221.11	301.31	503.43

Cash Flow

Abridged

Understanding Cash Flow Statement

Gujarat Themis Biosyn Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	-1.24	2.38	5.87	6.07	5.32	5.30	5.52	3.27	24.88	30.85	46.03	57.78	62.61	58.05	60.51
Working Capital - Increase/(Decrease)	3.14	-2.72	-2.23	-3.69	-1.70	-2.82	-0.11	-2.45	-24.30	-19.98	-4.36	-15.11	4.19	36.88	-17.88
Net CF from Operating Activities	1.90	-0.34	3.64	2.37	3.62	2.48	5.42	0.82	0.58	10.87	41.67	42.66	66.81	94.93	42.63
Capital Expenditures - Net	3.72	2.95	0.21	0.34	0.80	2.54	1.08	6.02	3.24	3.05	13.90	23.70	74.64	116.15	172.53
Net CF from Investing Activities	-3.65	-2.96	-0.41	-0.35	-0.88	-2.54	-1.08	-6.02	-3.25	-3.04	-31.40	-23.68	-57.90	-116.15	-172.54
Dividends Paid - Cash - Total	-	-	-	-	-	-	-	-	-	2.40	10.00	12.44	6.90	1.82	7.30
Stock - Issuance/(Retirement) - Net	-	2.93	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	1.90	-0.07	-2.60	-2.73	-2.75	0.16	-3.57	5.42	2.42	-2.32	-3.79	-0.75	-1.60	28.26	128.64
Net Cash Flow from Financing Activities	1.90	2.86	-2.60	-2.73	-2.75	0.16	-3.57	5.42	2.42	-4.71	-13.79	-13.19	-8.50	26.44	121.33
Free Cash Flow to Equity	0.09	-3.37	0.83	-0.70	0.07	0.10	0.77	0.22	-0.24	5.51	23.99	18.21	-9.43	7.04	-1.27
Free Operating CF net dividend	-1.98	-3.40	3.43	1.97	2.82	-0.06	4.34	-10.53	-2.66	5.42	17.78	6.53	-14.74	-23.03	-137.20
Free Operating CF	-1.98	-3.40	3.43	1.97	2.82	-0.06	4.34	-10.53	-2.66	7.81	27.78	18.96	-7.84	-21.22	-129.90

Business Segment Analysis

FY End:

Mar 25

Gujarat Themis Biosyn Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Manufacturing bulk drugs (100.0%)₹ 116.15 Cr

Revenue / Sales

Manufacturing bulk drugs (100.0%)₹ 150.80 Cr

Assets

Manufacturing bulk drugs (100.0%)₹ 301.31 Cr

Operating Income

Manufacturing bulk drugs (100.0%)₹ 63.47 Cr

Regional Segment Analysis

Gujarat Themis Biosyn Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Gujarat Themis Biosyn Ltd.

Historical Segment Analysis

Track how Gujarat Themis Biosyn Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2023 Mar 31	2024 Mar 31	2025 Mar 31

Manufacturing bulk drugs	24	75	116

Frequently Asked Questions

What is the revenue of Gujarat Themis Biosyn Ltd.?

The latest trailing twelve month revenue of Gujarat Themis Biosyn Ltd. is ₹ 165.82 Cr, reflecting a 1-year growth of 9.96% and a 3-year CAGR of 3.64%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Gujarat Themis Biosyn Ltd.?

The latest trailing twelve month net profit (PAT) of Gujarat Themis Biosyn Ltd. is ₹ 46.68 Cr, with a 3-year earnings CAGR of -6.99%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Gujarat Themis Biosyn Ltd.?

The operating margin of Gujarat Themis Biosyn Ltd. is -. Detailed EBITDA history is available in the Income Statement section of the Statements tab.

What is the EPS of Gujarat Themis Biosyn Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Gujarat Themis Biosyn Ltd. is 4.28. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Gujarat Themis Biosyn Ltd.?

The debt-to-equity ratio of Gujarat Themis Biosyn Ltd. stands at 0.56. The interest coverage ratio is 21.23x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Gujarat Themis Biosyn Ltd.?

The estimated book value per share of Gujarat Themis Biosyn Ltd. is 26.41 (derived from a P/B ratio of 14.00 and market price of ₹ 369.60), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Gujarat Themis Biosyn Ltd.?

The trailing twelve month operating cash flow of Gujarat Themis Biosyn Ltd. is ₹ 42.63 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Gujarat Themis Biosyn Ltd. report consolidated or standalone financials?

Gujarat Themis Biosyn Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.